Reed Sarah Burgess bought VOR
September 8, 2025 · Form 4 insider transaction
Reed Sarah Burgess bought 60,000 shares of Vor Biopharma Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on September 8, 2025, in each case subject to the Reporting Person's continued service as of each such date.; Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.